Skip Navigation


European Heart Journal Advance Access originally published online on August 7, 2006
European Heart Journal 2006 27(17):2034-2035; doi:10.1093/eurheartj/ehl019
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/17/2034    most recent
ehl019v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Goette, A.
Right arrow Articles by Schotten, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goette, A.
Right arrow Articles by Schotten, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Inhibition of angiotensin II type 1 receptors reduces atrial stunning and spontaneous echo contrast after electrical cardioversion of atrial fibrillation

Andreas Goette1,* and Ulrich Schotten2

1 Division of Cardiology, University Hospital Magdeburg, Leipzigerstr. 44, 39120 Magdeburg, Germany
2 Department of Physiology, University Maastricht, PO Box 616, 6200 MD Maastricht, The Netherlands

* Corresponding author. Tel: +49 391 6713225; fax: +49 391 673202. E-mail address: andreas.goette@medizin.uni-magdeburg.de

This editorial refers to ‘Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation’{dagger} by N. Dagres et al., on page 2062

The first 10% of the full text of this article appears below.

Atrial fibrillation (AF) is known to be an important risk factor for thrombo-embolism.1,2 AF has been shown to induce a prolonged mechanical dysfunction of the atria, which becomes apparent after successful conversion of AF to normal sinus rhythm.1–4 The reduced mechanical function after termination of AF has been termed atrial stunning. Atrial stunning has been described after electrical (DC shock, overdrive pacing, catheter ablation), pharmacological, and spontaneous cardioversion of AF, which demonstrates that AF itself, rather than the mode of conversion, induces mechanical dysfunction. Pathophysiologically, the transient dysfunction of the atria appears to be due to abnormalities in cellular calcium handling and reduced calcium transient through L-type calcium channels.1,3 Furthermore, destruction of contractile proteins by calcium-dependent proteases such . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation
Nikolaos Dagres, George Karatasakis, Fotios Panou, Georgios Athanassopoulos, Themistoclis Maounis, Elias Tsougos, Kallirrhoe Kourea, Ioannis Malakos, Dimitrios Th. Kremastinos, and Dennis V. Cokkinos
EHJ 2006 27: 2062-2068. [Abstract] [FREE Full Text]